A liposome system combining tumor-penetrating peptide NGR and cell-penetrating peptide R9 delivered doxorubicin deep into tumors by overcoming multiple biological barriers.
Multi-barrier penetrationCombining tumor-targeting and cell-penetrating peptides achieved synergistic deep tumor drug delivery that neither peptide accomplished alone
What the researchers found
Liposomes coated with both tumor-penetrating (cyclic iNGR) and cell-penetrating (R9) peptides achieved synergistic penetration of multiple biological barriers, delivering doxorubicin deep into tumor tissue and cells in vitro and in vivo.
Why it matters
Many cancer drugs are effective at killing cancer cells in a dish but fail in patients because they cannot penetrate solid tumors deeply enough. This dual-peptide approach solves multiple penetration barriers simultaneously, potentially making existing drugs more effective.
The numbers in context
The modified NGR peptide demonstrated enhanced multi-barrier penetration compared to the original iNGR tumor-penetrating peptide.
How the study worked
Developed Lip-mbPDS liposomes coated with R9 CPP and cyclic iNGR peptide. Tested in CD13-positive HT1080 fibrosarcoma cells using confocal microscopy, cell internalization/toxicity assays, 3D tumor spheroid penetration, and in vivo antitumor efficacy in mouse models.
Who was studied
Tumor-bearing mice treated with NGR peptide-based nanotherapeutics
What this study cannot tell us
Preclinical study using a single tumor model (HT1080 fibrosarcoma). Different tumor types may present different penetration challenges. Liposome stability and manufacturing scalability not addressed. Clinical translation requires extensive safety and efficacy testing in humans.
How to read the evidence
Preliminary evidence: proof-of-concept preclinical study with promising in vitro and in vivo results in a single tumor model. Far from clinical application.
When this study was published
Published in 2024. Represents current advances in peptide-based tumor-penetrating drug delivery.
The bigger picture
The tumor penetration problem is one of the biggest unsolved challenges in cancer drug delivery. By combining peptides that solve different barriers — one for getting into the tumor and another for getting into cells — this synergistic approach demonstrates a general strategy that could improve the delivery of many existing cancer drugs.
Questions still open
- Does this dual-peptide system improve outcomes across different solid tumor types, especially dense tumors like pancreatic cancer?
- Can the system be loaded with drugs other than doxorubicin, including newer immunotherapy agents?
- What is the safety profile of this multi-peptide system in normal tissues?
Common questions
Why can't regular cancer drugs reach tumors?
What are tumor-penetrating peptides?
Read the original research
Multibarrier-penetrating drug delivery systems for deep tumor therapy based on synergistic penetration strategy.
Biomaterials science, 12(9), 2321-2330
Citation
Zhang, Hui-Feng; Yu, Huan; Pan, Shuang-Xue; Zhang, Chuang; Ma, Ying-Hui; Zhang, Yan-Fei; Zuo, Li-Li; Hao, Cheng-Yi; Lin, Xiao-Ying; Geng, Hao; Wu, Di; Mu, Shang-Qiang; Yu, Wei-Lun; Shi, Nian-Qiu. (2024). Multibarrier-penetrating drug delivery systems for deep tumor therapy based on synergistic penetration strategy.. Biomaterials science, 12(9), 2321-2330. https://doi.org/10.1039/d3bm01959d